ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

ET on Friday, July 30, 2021 to discuss its second quarter operating results.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, July 15, 2021
Information
Tags: 
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Clinical medicine, Medical specialties, Medicine, Immunology, Antineoplastic drugs, Biotechnology, Antibody-drug conjugate, ImmunoGen, ImmunoGen, Monoclonal antibodies
Geotags: 
United States, Massachusetts
⚠generated by AI ↴
Summary
Key Points: 
  • ET on Friday, July 30, 2021 to discuss its second quarter operating results.
  • To access the live call by phone, dial (877) 621-5803; the conference ID is 1789134.
  • The call may also be accessed through the Investors and Media section of the Companys website, www.immunogen.com .
  • ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.


ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 30, 2021 to discuss its second quarter operating results. Management will also provide a brief update on the business.

Conference Call Information

To access the live call by phone, dial (877) 621-5803; the conference ID is 1789134. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Copyright: 
Copyright Business Wire 2021